Skip to content

NET in Iranian Women Suffering From Post Traumatic Stress Symptoms

Efficacy of Narrative Exposure Therapy (NET) in a Sample of Iranian Women Exposed to Intimate Partner Violence (IPV)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01731418
Enrollment
34
Registered
2012-11-21
Start date
2012-11-30
Completion date
2015-12-31
Last updated
2017-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Domestic Violence, Mental Disorders

Keywords

Post Traumatic Stress Disorder, Depression, Intimate Partner violence, Narrative Exposure Therapy

Brief summary

The proposed study seeks to investigate to what extent Narrative Exposure Therapy (NET) is an effective treatment for the reduction of symptoms of Post-Traumatic Stress Disorder (PTSD) and depression and for the improvement of daily functioning in Iranian women who have experienced intimate partner violence (IPV). In addition, the study seeks to investigate whether NET therapy could lead to the reduction of Intimate Partner Violence (IPV) within their marriage.

Interventions

BEHAVIORALNarrative Exposure Therapy

Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, & Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.

OTHERTreatment-as-usual

Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling. Regarding supportive counselling, the sessions included: Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills

Sponsors

Tehran University of Medical Sciences
CollaboratorOTHER
University of Konstanz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* being victims of Intimate Partner Violence and seeking help at target clinics in order to reduce their psychological symptoms, currently living together with their partner/husband, meeting the set cut-off point on the PTSD scale according to DSM-IV.

Exclusion criteria

* schizophrenia, epilepsy, mental retardation, drug abuse and mal-nourishment

Design outcomes

Primary

MeasureTime frameDescription
Posttraumatic Diagnostic Scale (PDS/PSS-I).Symptoms will be assessed at pre-treatment-point and post-treatment-point (up to 6-month follow-ups)The PDS/PSS-I is a 17-item screening instrument on a 4-point-Likert-scale (0 = not at all to 3 = very much). The PDS aims at assessing all Diagnostic and Statistical Manual (DSM-IV) criteria of a Post Traumatic Stress Disorder (PTSD), and thus it includes information about the nature of the traumatic event and the level of functional interference.
The Patient Health Questionnaire-9 (PHQ-9)At pre-treatment-point, post-treatment-point, and 3- and 6-month follow-upsThe Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders. The PHQ-9 is the depression module
The Hopkins Symptom Checklist-25 (HSCL-25)At pre-treatment-point, post-treatment-point, and 3- and 6-month follow-upsThe Hopkins Symptom Checklist 25 would be used to screen for symptoms of depression and anxiety.
Perceived Stress Scale-4At pre-treatment-point, post-treatment-point and 3- and 6-month follow-upsThe Perceived Stress Scale (PSS) would be used to assess the perception of stress over the course of the last month preceding the interview

Secondary

MeasureTime frameDescription
Checklist of family violenceAt pre-treatment-point, post-treatment-point and 3- and 6-month follow-upsThis checklist assessing the incidence of domestic violence was developed by Catani (2002) and includes questions on physical abuse, verbal violence, neglect and sexual abuse as well as witnessing intimate partner violence between parents.
Composite Abuse Scale (CAS)At pre-treatment-point, post-treatment-point, and 3- and 6-month follow-upsThe CAS, a 30-item validated research instrument, is a widely used self-report questionnaire of behaviors that women describe as abusive by their partners. It is a self-report measure that provides standardized sub scale scores on four dimensions of intimate partner abuse. The four dimensions are Severe Combined Abuse, Emotional Abuse, Physical Abuse, and Harassment, scaled from 0 (never) to 5 (daily) over a period of 12-month.
The Work and Social Adjustment Scale (WSAS)At pre-treatment-point, post-treatment-point and 3- and 6-month follow-upsThe WSAS is a widely used 5-item measure of disability. Its psychometric properties were analyzed and shown in different studies and disorders (Mataix-Cols et al, 2005; Mundt et al, 2002).
The Life Events ChecklistAt pre-treatment-point, post-treatment-point and 3- and 6-month follow-upsThe Life Events Checklist (LEC) is a brief, 17-item, self-report measure designed to screen for potentially traumatic events in a respondent's lifetime. The LEC assesses exposure to 16 events known to potentially result in PTSD or distress and includes one item assessing any other extraordinarily stressful event not captured in the first 16 items.

Other

MeasureTime frameDescription
Borderline Symptom List (BSL-23)At pre-treatment-point, post-treatment-point and 3- and 6-month follow-upsThe BSL-23 is a shortened form of the full version of the BSL-95. The self-report questionnaire assesses borderline-specific symptomatology on a five response scale ranging from 0 (not at all) to 4 (very strongly).

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026